3 q14 presentation

Third Quarter 2014 Financial Results Conference Call
October 20, 2014

1
Forward-looking Statements
This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements include, but are not limited to, statements regarding Valeant Pharmaceuticals International, Inc.’s (“Valeant”) business development activities, including the timing of closing of pending transactions, clinical results and timing of development products, timing of expected product launches and its expected future performance (including expected results of operations, outlook and financial guidance), and Valeant’s offer to acquire Allergan, Inc. (“Allergan”) and the combined company’s future financial condition, operating results, strategy and plans. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” “opportunity,” “tentative,” “positioning,” “designed,” “create,” “predict,” “project,” “seek,” “ongoing,” “upside,” “increases” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to numerous assumptions, risks and uncertainties that change over time and could cause actual results to differ materially from those described in the forward-looking statements. These assumptions, risks and uncertainties include, but are not limited to, assumptions, risks and uncertainties discussed in Valeant’s most recent annual and quarterly report filed with the Securities and Exchange Commission (the “SEC”) and the Canadian Securities Administrators (the “CSA”) and assumptions, risks and uncertainties relating to the proposed merger, as detailed from time to time in Valeant’s filings with the SEC and the CSA, which factors are incorporated herein by reference. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this communication are set forth in other reports or documents that we file from time to time with the SEC and the CSA, and include, but are not limited to:
the ultimate outcome of any possible transaction between Valeant and Allergan including the possibilities that Valeant will not pursue a transaction with Allergan and that Allergan will reject a transaction with Valeant;
if a transaction between Valeant and Allergan were to occur, the ultimate outcome and results of integrating the operations of Valeant and Allergan, the ultimate outcome of Valeant’s pricing and operating strategy applied to Allergan and the ultimate ability to realize synergies;
the effects of the business combination of Valeant and Allergan, including the combined company’s future financial condition, operating results, strategy and plans;
the effects of governmental regulation on our business or potential business combination transaction;
ability to obtain regulatory approvals and meet other closing conditions to the transaction, including all necessary stockholder approvals, on a timely basis;
our ability to sustain and grow revenues and cash flow from operations in our markets and to maintain and grow our customer base, the need for innovation and the related capital expenditures and the unpredictable economic conditions in the United States and other markets;
the impact of competition from other market participants;
the development and commercialization of new products;
the availability and access, in general, of funds to meet our debt obligations prior to or when they become due and to fund our operations and necessary capital expenditures, either through (i) cash on hand, (ii) free cash flow, or (iii) access to the capital or credit markets;
our ability to comply with all covenants in our indentures and credit facilities, any violation of which, if not cured in a timely manner, could trigger a default of our other obligations under cross-default provisions; and
the risks and uncertainties detailed by Allergan with respect to its business as described in its reports and documents filed with the SEC.
All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this communication or to reflect actual outcomes, expected as required by applicable law.

2
More Information
ADDITIONAL INFORMATION
This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates, in part, to the exchange offer which Valeant has made to Allergan stockholders. The exchange offer is being made pursuant to a tender offer statement on Schedule TO (including the offer to exchange, the letter of election and transmittal and other related offer materials) and a registration statement on Form S-4 filed by Valeant with the SEC on June 18, 2014 and with the CSA, as each may be amended from time to time. These materials, as they may be further amended from time to time, contain important information, including the terms and conditions of the offer. In addition, Valeant has filed a preliminary proxy statement with the SEC on June 24, 2014, as may be amended from time to time, Pershing Square Capital Management, L.P. (“Pershing Square”) has filed a definitive proxy statement with the SEC on September 24, 2014, and Valeant and Pershing Square (and, if a negotiated transaction is agreed, Allergan) have filed or may file one or more additional proxy statements or other documents with the SEC. This communication is not a substitute for any proxy statement, registration statement, prospectus or other document Valeant, Pershing Square and/or Allergan may file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF VALEANT AND ALLERGAN ARE URGED TO READ THE TENDER OFFER STATEMENT, REGISTRATION STATEMENT AND ANY OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any definitive proxy statement(s) (if and when available) will be mailed to stockholders of Allergan and/or Valeant, as applicable. Investors and security holders may obtain free copies of the tender offer statement, the registration statement and other documents (if and when available) filed with the SEC by Valeant and/or Pershing Square through the web site maintained by the SEC at http://www.sec.gov.
Information regarding the names and interests in Allergan and Valeant of Valeant and persons related to Valeant who may be deemed participants in any solicitation of Allergan or Valeant shareholders in respect of a Valeant proposal for a business combination with Allergan is available in the additional definitive proxy soliciting materials in respect of Allergan filed with the SEC by Valeant on April 21, 2014, May 28, 2014 and September 25, 2014. Information regarding the names and interests in Allergan and Valeant of Pershing Square and persons related to Pershing Square who may be deemed participants in any solicitation of Allergan or Valeant shareholders in respect of a Valeant proposal for a business combination with Allergan is available in additional definitive proxy soliciting material in respect of Allergan filed with the SEC by Pershing Square. The additional definitive proxy soliciting material referred to in this paragraph can be obtained free of charge from the sources indicated above.
Consent was not obtained nor sought with respect to third party statements referenced in this presentation.
Non-GAAP Information To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), Valeant uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & property, plant and equipment step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition-related and other costs, In-process research and development, impairments and other charges, ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization including intangible asset impairments and other non-cash charges, amortization and write-down of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets sold/held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of Valeant’s core operating results and trends for the periods presented. Non- GAAP financial measures are not prepared in accordance with GAAP. Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non- GAAP reconciliations can be found in our press tables under the Investor Relations tab on www.valeant.com.

3
Agenda
1.Third Quarter 2014 Results
2.Business Highlights and Outlook
3.Financial Review and Updated Guidance
4.Allergan Update

4
Q3 2014 Results
Q3 2014
Q3 2013
% Growth
Total Revenue
$2.1 B
$1.5 B
33%
Cash EPS
$2.11
$1.43
48%
GAAP Cash Flow from Operations
$619 M
$202 M
207%
Adjusted Cash Flow from Operations
$771 M
$408 M
89%
Cash Conversion
107%
84%

5
Q3 2014 Results
Guidance
Q3 2014
Results
Q3 2014
Organic Growth – Company Same Store Sales
Second half of year high single digit
19%
Organic Growth – B&L
Second half of year double digit
12%
Total Revenue
$1.9B - $2.1B
$2.1B
Cash EPS
$1.90 - $2.00
$2.11
Second half of year ~$1.3B
$771M
Restructuring
<$70M
$63M
Total revenue at high end of guidance despite FX impact of $(31M)
Cash EPS FX Impact of $(0.04)

6
Q3 2014 Organic Growth Including All Generic Impact
(a)As reported.
(b)Excludes injectables for Q1 in YTD organic growth.
Same Store Sales – YoY growth rates for businesses that have been owned for one year or more
Q1 2014(a)
Q2 2014(a)
Q3 2014
YTD 2014(b)
Total U.S.
2%
5%
29%
15%
Total Developed
1%
2%
22%
11%
Total Emerging Markets
3%
8%
12%
9%
Total Company
1%
4%
19%
11%
Pro Forma – YoY growth rates for entire business, including those that have been acquired within the last year
Q1 2014(a)
Q2 2014 (a)
Q3 2014
YTD 2014 (b)
Total U.S.
3%
9%
24%
13%
Total Developed
3%
7%
18%
10%
Total Emerging Markets
4%
10%
9%
8%
Total Company
4%
8%
16%
10%

7
Bausch + Lomb Organic Growth (adjusted for only FX)
Country/Region
Q3 2014
Product Sales
Q/Q%
Since Ownership
(8/5/13)
CAGR
United States
$369M
18%
12%
Consumer
$104M
17%
13%
Rx Pharma
$107M
25%
9%
Surgical
$53M
10%
12%
Contact Lens
$45M
23%
14%
Generics
$60M
12%
17%
Other Developed
Markets
$256M
5%
5%
Emerging Markets
$217M
11%
13%
Total
$843M
12%
10%

8
Q3 Organic Growth Drivers
Turnaround in U.S. Dermatology performance has accelerated with the launches of Jublia®, LuzuTM, and RAM 0.08%
Strong double digit growth in the B+L businesses globally
Continued strong performance in Emerging Markets (12% organic growth), despite geopolitical uncertainties
At or above our forecasted growth in most of our other businesses
U.S. Dentistry – driven by expanded sales force
U.S. Neuro/Generics – growth in Xenazine, Wellbutrin XL, and orphan products and the impact of competitive stock outs on certain generic products
Obagi – driven by improved sales force effectiveness
More growth from volume than price for total company

9
Q3 2014 Top 20 Global Brands (1/3)
Top 20 products YTD revenue of $1.8B, representing 31% of total revenue
Top 20 products grew 32% Q3 2014 over Q3 2013 and 16% YTD
All 20 products grew in Q3 2014 over Q3 2013
~50% of Q3 growth from volume for top 20 products
Top 20 products demonstrate diversification
Largest product contributed ~3.5% of Q3 2014 revenue
Top 10 products contributed 22% of Q3 2014 revenue
Mix of products includes Rx, OTC and devices (solutions)
Jublia® was 28th largest product in Q3 2014, anticipated to be in top 20 products in Q4

10
Q3 2014 Top 20 Global Brands (2/3) ($ in M)
Product
Q3 2014 Revenue
Primary Growth Driver
2014 YTD Revenue
1)
Wellbutrin®
$72
Volume
$195
2)
Ocuvite®/PreserVision®
$62
Volume
$188
3)
Xenazine® US
$56
Volume
$160
4)
Solodyn®
$54
Volume
$148
5)
Targretin® Capsules
$44
Price + Volume
$88
6)
ReNu Multiplus®
$41
Volume
$145
7)
Lotemax® Franchise
$35
Price
$106
8)
Arestin®
$30
Price
$75
9)
Retin-A® Franchise
$30
Volume
$68
10)
BioTrue® Solution
$26
Volume
$77

11
Q3 2014 Top 20 Global Brands (3/3) ($ in M)
Product
Q3 2014 Revenue
Primary Growth Driver
2014 YTD Revenue
11)
ArtelacTM
$25
Volume
$76
12)
Zovirax® Franchise
$23
Price
$82
13)
Elidel®
$22
Price + Volume
$72
14)
CeraVe®
$21
Volume
$68
15)
Syprine®
$20
Price
$57
16)
Boston Solutions
$20
Price
$59
17)
Cardizem® CD AG
$18
Volume
$26
18)
Ziana®
$17
Volume
$45
19)
Duromine®
$17
Volume
$45
20)
Prolensa®
$16
Volume
$46
28)
Jublia
$12
Volume
$15

12
Q3 U.S. Business Highlights (1/3)
Dermatology, $273M Revenues, 33% Q/Q Growth
Strong growth for promoted brands, e.g. Solodyn, Elidel, Acanya®, Zyclara®
After only three months, Jublia has 7% TRx share of total onychomycosis market
Luzu TRx uptake continues to accelerate with 13% share of branded topical antifungal market
Includes PreCision since acquisition closed on July 7
Consumer, $141M Revenues, 43% Q/Q Growth
One of the fastest growing OTC Health Care company in the US (September YTD)(a)
CeraVe - fastest growing (Major) skin care brand(a)
PreserVision AREDS 2 - #1 selling Vitamin over last 12 weeks(a)
Entire PreserVision brand grew 20% Q/Q based on consumption(a)
BioTrue Multipurpose Solution - Fastest growing Lens Care brand(a)
(a)Source: IRI consumption data.

13
Ophthalmology Rx, $118M Revenues, 57% Q/Q Growth
Strong performance of Anti-infective/Anti-viral portfolio – Besivance®, Zylet®, Zirgan®
Continued Q/Q organic growth from Prolensa +11% and Lotemax Franchise +13%
Contact Lenses, $45M Revenues, 82% Q/Q Growth
Fastest growing contact lens business – market share expanded from 7% to over 10% since B+L acquisition(a)
BioTrue ONEday and PureVision® 2 for Presbyopia exceeding expectations and capturing market share; current growth doesn’t reflect upside in Bausch + Lomb Ultra ® given limited distribution (less than $5M of revenues in Q3 2014)
(a)Source: Independent third party data.

14
Surgical, $54M Revenues, 74% Q/Q Growth
Greater than 55% growth for the cataract refractive lens business
Greater than 40% growth for Stellaris® and Stellaris PC
Number two player in the Posterior Chamber IOL market(a)
28 Victus® machines expected to be installed in 2014 in the U.S., compared with 14 installed in 2013
Neuro & Other/Generics, $392M Revenues, 40% Q/Q Growth
Neuro growth driven by promoted brands – Xenazine, Wellbutrin XL® and Syprine/Cuprimine®
Continued growth of generics through portfolio expansion and due to competitor stock outs
Dental, $32M Revenues, 20% Q/Q Growth
Growth driven by new customers and strong early performance of launch products (e.g. Onset)
Aesthetics, $32M Revenues(b)
Improved sales force effectiveness resulted in 21% Q/Q organic growth for Obagi
(a)Source: Market Scope, an ophthalmic market research firm, based on data as of Q2 2014.
(b)No injectables revenues in Q3 2014.

15
Q3 Rest of World Business Highlights
Emerging Markets-Europe/Middle East, $279M Revenues, 36% Q/Q Growth
Strong performance across all regions even with significant FX headwinds
FX impacts on European Emerging Markets ~ $(18M) Revenues (relative to 7/31 Guidance)
Q/Q organic growth in Russia, Ukraine and CIS of ~20%
Emerging Markets-Asia/Africa, $155M Revenues, 66% Q/Q Growth
China organic growth of 11% driven primarily by lens franchise
iNova South-East Asia business organic growth of 18% Q/Q
Emerging Markets-Latin America, $114M Revenues, 13% Q/Q Growth
Strong performance in Mexico of 12% organic growth, following resolution of supply issues
Brazil and Argentina impacted by economic slowdown and import restrictions in Argentina
Export business negatively impacted by capital controls in Venezuela
ROW Developed, $421M Revenues, 29% Q/Q Growth
Australian organic growth of 15% due to strong cough & cold season
Japanese lens care is gaining market share
Continued mid-single digit organic growth in Western Europe
Offset by a decline in Canada largely due to genericization of Wellbutrin® XL and FX impact

16
JUBLIA Growth Accelerating by Comprehensive Campaign
5,831 TRxs/week
U.S. Weekly TRx Volume
Total Prescriptions (TRx)
5,462 TRxs/month
Source: IMS Compuscript for month ending 9/30.
Source: Wolters Kluwer Pharmaceutical + Specialty Pharmacy Data week ending 10/10.
Canada Monthly TRx Volume

17
asd
Physician Website
Physician eBlast/Banners
Physician Journal Ads
Speaker Programs Webinars Medical Education Ad Boards
Consumer Website
Consumer Banners
Consumer Print
Physician Campaign
JUBLIA Growth Accelerating by Comprehensive Campaign
Print and digital advertising rolled out 2H Q3
TV advertising materials recently reviewed by FDA; expected to be on air mid-Q4
Salesforce focused on Jublia
U.S.: ~60 person podiatry and ~90 dermatology reps; Canada: ~ 25 dermatology reps
Decision to shift spend from a contracted primary care sales force to additional dermatology reps and consumer advertising
Consumer Campaign

18
-
200
400
600
800
1,000
1,200
1,400
1,600
3/28/2014
4/11/2014
4/25/2014
5/9/2014
5/23/2014
6/6/2014
6/20/2014
7/4/2014
7/18/2014
8/1/2014
8/15/2014
8/29/2014
9/12/2014
9/26/2014
10/10/2014
Luzu TRx Volume Now Accounts for 13% of
Branded Topical Antifungal Market
Luzu Weekly TRx Volume
1,335 TRxs/week

19
Retin-A Micro® 0.08% Exceeded 1,400 TRx’s Through Week of October 10th
1,443 TRx/week
Retin-A Micro 0.08% Weekly TRx Volume

20
Update on Other U.S. Product Launches
Bausch + Lomb Ultra
Expanding sales force by 50% to reach peak distribution
Lines 1 and 2 being installed; lines 3 and 4 ordered
Commercial quantities from line 1 expected Q2 2015
Selling to capacity (pilot line)
BioTrue ONEday – contact lens
2nd consecutive quarter with greater than 90% growth
BioTrue Multi-purpose Solution
Grew 56% Q/Q pro forma
TrulignTM Toric IOL
213% Q/Q pro forma growth
Victus
28 Victus machines expected to be installed in 2014, compared with 14 installed in 2013
CeraVe BabyTM (Q1), Peroxiclear (Q2) ® and SootheXPTM (Q3)
Continue to promote to and gain recommendations from dermatologists and eye care professionals
Sales and market share building

21
Near-Term Launch/Pipeline Update (1/2)
Product
Description
Expected Launch Date
Highlights
Adrenaline auto-injector for anaphylaxis
European launch 1H 2014; U.S. launch late 2016 / early 2017
•Strong start in Europe, with 20%+ market share in Sweden and U.K., ~6% share in Germany
OnextonTM
Acne
January 2015
•New combination acne product
•PDUFA date of November 30, 2014
VesneoTM
Glaucoma
2016
•Positive Phase 3 results
•NDA to be filed in 1H2015
•Peak sales potential of ~$500M in the US and ~$1B globally
Next Gen 0.38%
Post-Operative Inflammation and Pain
2016
•First twice-daily ophthalmic steroid
•Positive Phase 3 results
•2nd Phase 3 initiated
•NDA to be filed in 3Q2015

22
Near-Term Launch/Pipeline Update (2/2)
Product
Description
Expected Launch Date
Highlights
Hydrating Cleansing Bar
January 2015
•Locks in moisture 3x longer than the leading cleansing bar (Dove) and 6x longer than Cetaphil bar
SA Cleanser, Baby Cream, Baby Sunscreen SPF 45, Night Cream, Anti-Itch
Various
•Continues brand expansion
Gummies
Eye Health
Q1 2015
•Continues brand expansion
•Gummies is the fastest growing vitamin category
Brimonidine
Eye Whitening
2016
•Recent completion of Phase 3 studies
•Planned NDA submission Q1 2015

23
Continued Growth Through Business Development
Acquisitions Closed since Q2 Earnings(a)
Bescon – Asia
Contact lenses, full range of modalities for both clear and color, and daily silicone hydrogel lenses
Global opportunity
PT Armoxindo Farma – Indonesia
Branded generics
Acquisitions Closed in Q4
MedPharma – Middle East and North Africa
Branded generics platform including manufacturing
Zarracom – Turkey
Acrylic hydrophobic IOLs
Acquisitions signed since Q2 Earnings
Croma – Europe
Expanding existing Central and Eastern European rights to global rights; existing sales concentrated in Western Europe
Surgical products including viscolelastics, IOLs and instruments; dry eye and anti- inflammatory pharmaceuticals
(a) ~$2M revenue impact from closed deals in Q3 2014.

Financial Outlook
Howard Schiller

25
Financial Summary
Q3 2013
Q4 2013
Q1 2014
Q2 2014
Q3 2014
Total Revenue
$1,542M
$2,064M
$1,886M
$2,041M
$2,056M
Cost of Goods Sold% (% of product sales)
27%
26%
26%
28%
26%
SG&A% (% of total revenue)
23%
22%
26%
25%
24%
R&D Expense
$49M
$60M
$61M
$66M
$59M
Operating Margin (% of total revenue)
(excluding amortization)
47%
49%
45%
44%
47%
Cash EPS (Reported)
$1.43
$2.15
$1.76
$1.91
$2.11
$202M
$280M
$484M
$376M
$619M
$408M
$607M
$636M
$500M
$771M
Fully Diluted Share Count
340 M
341 M
342 M
341M
341M

26
Significant Q3 FX headwinds - Revenue: $(31)M; Cash EPS: $(0.04)
FX Impact on Q3/Q4 versus 7/31 Guidance
(a) Order is based on actual financial impact versus outlook as of July 31, 2014.
Q4 impact
• Revenue: ~$(53)M
•Cash EPS: ~$(0.06) (assuming current rates)
Russian Ruble(14.6)% Euro(4.4)% Polish Zloty(6.2)% Canadian Dollar(3.6)% Japanese Yen(3.0)% Brazilian Real(9.5)% Serbian Dinar(6.4)% Australian Dollar(6.2)% Mexican Peso(3.5)% British Pound(5.8)% South African Rand(4.5)% Argentine Peso(3.6)% Indian Rupee(1.9)% Hungarian Forint(3.4)% Currency(a) 10/15/14 Spot % Change vs. 7/31/14

27
Restructuring and Integration Update
B+L Restructuring and Integration charges were $36M for the quarter, down from $53M in Q2
Restructuring and Integration charges for deals completed in Q3 (PT Armoxindo Farma, Bescon) were ~$3M for the quarter
Due to uncertain timing of close, these expenses were not included in restructuring expense estimate presented on 7/31
Restructuring and Integration charges expected to further decline in Q4 to less than $50M Q4 14 and less than $25M in Q1 15, assuming no additional deals
Q2 14
Q3 14
Q4 14
Q1 15
Estimate
Estimate
Restructuring / Integration Expense
$143M
$63M
< $50M
< $25M

28
Cash Flow from Operations
Guided to cash conversion of 90%
Q1 14
Q2 14
Q3 14
YTD
Adjusted Net Income
600
651
719
1,969
484
376
619
1,479
636
500
771
1,907
Cash Conversion
106%
77%
107%
97%
Investment in Working Capital
43
166
<10
~219

29
Balance Sheet
Significant deleveraging in Q3
$1.1B Term Loan repaid in Q3 resulting in $16.3B debt outstanding
Net leverage ratio reduced to ~4.0 times adjusted pro forma EBITDA
In addition, on October 15, redeemed $500M 6.75% senior notes due 2017
Accounts Receivable DSO have declined each quarter in 2014 (calculated using gross sales):
Q1 2014: 72 Days
Q2 2014: 66 Days
Q3 2014: 64 Days
Today and going forward, we will be disclosing gross sales to allow you to do this calculation
Due to changes in product mix and higher gross sales, accounts receivable increased by $109M with an offsetting increase in accrued liabilities of ~$90M related to rebates, returns and allowances
Net increase of ~$20M in receivables in Q3 vs. Q2 2014 against $30M increase in net sales
U.S. Rx wholesale inventory levels flat on a unit basis and down on a dollar basis vs. Q2 2014

30
Accelerated organic growth from <5% pre acquisition to 10% since acquisition (adjusted only for FX)
Continued strength of pharma
Turnaround for lens and surgical
Increased scale of combined Valeant and B+L consumer business has accelerated growth
Benefit from Valeant’s decentralized approach
Valeant’s emerging market capabilities have accelerated B+L’s emerging market growth
Successful recent product launches; limited contribution to date, will be growth drivers in future
Bausch + Lomb Ultra
BioTrue ONEday for Presbyopia
PureVision 2 for Presbyopia
Peroxiclear
On track to achieve at least $900 million in Bausch + Lomb synergies
~$800 million annualized run rate realized by Q3 14
Remainder of synergies expected to be achieved by end of 2015
Primarily related to manufacturing, Europe and small amounts from a number of other areas
Cost to achieve synergies expected to be ~$600M
Great people added at all levels to our organization
Victus
Trulign
enVista BLIS™ lens inserter
Soothe XP
B+L One Year Anniversary Update – Blueprint for Allergan

31
Q4 Outlook
Continued growth drivers for Q4
Confident in 10+% same store organic growth
Expect continued strong performance from Jublia and other recent product launches
Updated Q4 guidance
Revenues: unchanged
Based on current exchange rates, FX revenue impact would be ~$(53)M
Cash EPS: raised $0.10 to $2.45 to $2.55
Based on current exchange rates, FX Cash EPS impact would be ~$(0.06)
Reflects strong momentum of our overall business
Full year 2014 guidance
Revenues: from $8.0B - $8.3B to $8.1B - $8.3B
Cash EPS: from $7.90 - $8.10 to $8.22 - $8.32
Adjusted Cash Flow from Operations: from $2.3B - $2.6B to greater than $2.5B (expect at least 90% cash conversion for full year 2014)
Net leverage ratio reduced to ~3.9 times adjusted pro forma EBITDA by year end

32
2015 Outlook
July 31
2015 Outlook
Current
2015 Outlook
Rationale
2015 Revenue
Growth
(No acquisitions)
~$8.9 B
9%
~$9.1 B+
10%+
•Higher than expected 2H 2014 revenue, strength across all businesses and increasing confidence in Jublia
Gross Margins
74%
75%
•Q3 and Q4 gross margins better than expected
•Expected improved mix, declining Xenazine revenue and current cost improvement initiatives
SG&A Margins
Low to mid 20% as % of revenue
Low to mid 20% as % of revenue
•~23% - 24%
•Will continue to invest in launch products in 2015
Cash EPS
Assuming no acquisitions
~$9.40
~$10.00
•Cash EPS Growth Assuming No Acquisitions
•July 31st – 17%
•Oct 20th – 21%
Acquisitions -
Leverage stays at ~4.0x
or below
~$9.90
~$10.70

34
Allergan Update
We remain focused on completing the Allergan Transaction
Record date to vote at Special Meeting is October 30th
With T+3 settlement, shares need to be purchased by October 27th
Special Meeting will be held December 18th
Allergan shareholders need to remove a majority of directors in order for Allergan to be compelled to negotiate
The economic choice is clear
Receive greater than ~$20.00 of 2016 EPS per Allergan share in a combination with Valeant vs. ~$10.00 standalone Allergan EPS
VRX + AGN combination will generate significantly more synergies than any other combination

Appendix: Organic Growth Detail

36
Same Store Organic Growth Calculation
SAME STORE SALES ORGANIC GROWTH
CURRENT YEAR
PRIOR YEAR
Quarterly Product Sales
2,023.5
1,511.3
Subtract: Prior Year Revenue for Acquired Businesses (1)
343.5
-
Add/(Subtract): Year over Year Fx impact
24.9
Subtract: Divestitures and Discontinuations
81.7
Basis for Organic Growth Calculation
1,704.9
A
1,429.6
B
Same Store Organic Growth % = (A-B)/B
19%
(1) Revenue is subtracted for the period of time that the business was not owned in the prior year. For example, B+L was acquired on August 5th, 2013 so revenues from Jul 1 - Aug 5 2013 are excluded from the current year revenues

37
Pro Forma Organic Growth Calculation
PRO FORMA ORGANIC GROWTH
CURRENT YEAR
PRIOR YEAR
Quarterly Product Sales ($M)
2,023.5
1,511.3
Add: Prior Year Revenue for Acquired Businesses (1)
-
340.9
Add/(Subtract): Year over Year Fx impact
25.0
Subtract: Divestitures and Discontinuations
81.7
Basis for Organic Growth Calculation
2,048.5
A
1,770.5
B
Pro Forma Organic Growth % = (A-B)/B
16%
(1) Revenue is added for the period of time that the business was not owned in the prior year. For example, B+L was acquired on August 5th, 2013 so revenues from Jul 1 - Aug 5 2013 are added to the prior year revenues

Appendix: Accounts Receivable Details

39
Accounts Receivable
Q1 14
Q2 14
Q3 14
YTD 14
Gross Revenue (A)
2,451
2,750
2,980
8,180
Provisions for Returns, Rebates and Allowances
599
756
957
2,312
Net Revenue
1,851
1,994
2,023
5,868
Percentage of provisions to gross sales
24%
27%
32%
28%
Gross Accounts Receivable (B)
1,955
2,022
2,112
Provisions for Cash Discounts, Chargebacks, DSA fees and Doubtful Accounts
249
251
231
Net Accounts Receivable
1,706
1,771
1,880
Days Sales Outstanding = B/(A/90)
72
66
64

Appendix: Dermatology Rx Branded Share Among Dermatologists

41
Solodyn is capturing 48% of the Dermatologist share
CONFIDENTIAL
Source: PHAST Prescription Weekly & AF Data (week ending 10/10/14)

42
Acanya Has 88% Share Among Dermatologists
CONFIDENTIAL

43
Ziana (20% share) and Atralin (15% share) have grown in Dermatologists over the last 4 weeks
CONFIDENTIAL

44
Elidel continues to widen the share gap at 52% share among Dermatologists
CONFIDENTIAL

45
Zyclara has 41% share among Dermatologists
CONFIDENTIAL

3 q14 presentation

More Related Content

What's hot (20)

Similar to 3 q14 presentation (20)

More from Valeant_Pharmaceuticals (20)

Recently uploaded (20)

3 q14 presentation